ViewRay Akcija

ViewRay EBITDA

EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) no ViewRay (VRAYQ) uz 2026. g. 20. aug. ir -103,96 M USD. Iepriekšējā gadā EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) bija -105,82 M USD — izmaiņas -1,76 % (augstāks).

EBITDA

-103,96 MUSD

YoY

-1,76%

Pēdējoreiz atjaunināts:

EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) no ViewRay ir 2026 -103,96 M USD. EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) no ViewRay bija 2025 -105,82 M USD. Tas samazinās par -1,76% augstāks salīdzinājumā ar iepriekšējo gadu.
Access this data via the Eulerpool API

ViewRay Akciju analīze

Ko dara ViewRay? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par ViewRay akciju

ViewRay EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) 2026. gadā ir -103,96 M USD.

EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) no ViewRay mainījās no -105,82 M USD uz -103,96 M USD, kas atspoguļo -1,76 % izmaiņas. Vērtība ir augstāks nekā iepriekšējā gadā.

Vietnē Eulerpool varat atrast pilnīgu EBITDA (Peļņa pirms procentiem, nodokļiem, nolietojuma un amortizācijas) ViewRay vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

EBITDA mēra darbības veiktspēju pirms finanšu struktūras, nodokļu un naudā neizteikto izdevumu ietekmes.

EBITDA = EBIT + Nolietojums un amortizācija

Rādītāji ietekmē akciju vērtējumu, signalizējot par peļņas kvalitāti, finansiālo veselību un izaugsmes trajektoriju. Spēcīgi rādītāji parasti noved pie augstākiem vērtējumiem.

Access this data via the Eulerpool API

Peļņas un zaudējumu aprēķins — ViewRay

Visas kategorijas